Lemon, 1969 - Google Patents
Endocrine influences on human mammary cancer formation a critiqueLemon, 1969
View PDF- Document ID
- 17617245939881334686
- Author
- Lemon H
- Publication year
- Publication venue
- Cancer
External Links
Snippet
The possible relationship of abnormal C18 and C19 steroid excretions to fibrocystic disease and to carcinoma of the human female breast has been reviewed in relation to newer knowledge of estrogen receptor sites in uterine and mammary tissues. Proteins from these …
- 206010006187 Breast cancer 0 title abstract description 39
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lemon | Endocrine influences on human mammary cancer formation a critique | |
Sherman et al. | Inadequate corpus luteum function: a pathophysiological interpretation of human breast cancer epidemiology | |
Wang et al. | Hormonal studies in Klinefelter's syndrome | |
Vermeulen | The hormonal activity of the postmenopausal ovary | |
De Jong et al. | Ovarian secretion rates of oestrogens, androgens and progesterone in normal women and in women with persistent ovarian follicles | |
Siiteri | Steroid hormones and endometrial cancer | |
Evans et al. | Estrogen receptor concentration in normal and pathological human uterine tissues | |
Lykkesfeldt et al. | Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X‐linked ichthyosis | |
Tulchinsky et al. | The plasma estradiol as an index of fetoplacental function | |
OTTOSON et al. | Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration | |
Grattarola et al. | Androgens in breast cancer: II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women | |
Mikhail | Sex steroids in blood | |
Adami et al. | Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls | |
Spona et al. | Hormone serum levels and hormone receptor contents of endometria in women with normal menstrual cycles and patients bearing endometrial carcinoma | |
Jacobs et al. | Therapy-orientated diagnosis of secondary amenorrhoea | |
Reed et al. | The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer | |
Faure et al. | Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone‐releasing hormone (LH‐RH) agonist | |
Lucisano et al. | Ovarian and peripheral plasma levels of progestogens, androgens and oestrogens in post-menopausal women | |
Gual et al. | Inhibition of ovulation by estrogens | |
Davis et al. | Estradiol metabolism in pregnant and nonpregnant women | |
Pettersson et al. | Serum estrogens and androgens in women with endometrial carcinoma | |
KEUTMANN et al. | Individual urinary 17-ketosteroids of healthy persons determined by gas chromatography: biochemical and clinical considerations | |
Schenker et al. | Estradiol and testosterone levels in the peripheral and ovarian circulations in patients with endometrial cancer | |
ASCH et al. | Steroidogenesis in the postmenopausal ovary | |
Carlström et al. | Serum levels of total dehydroepiandrosterone and total estrone in postmenopausal women with special regard to carcinoma of the uterine corpus |